# A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies

Source: https://onco.cc/trials/nct05803018/  
OnCo record `nct05803018` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of BL-B01D1 in advanced solid tumours, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.

## Summary

A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies is a phase 1/2 interventional study registered as NCT05803018 by Sichuan Baili Pharmaceutical Co., Ltd., with 38 participants planned, started 2023-06-25 and due to reach its primary completion in 2026-12. Interventions recorded: BL-B01D1.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05803018
- Phase: 1/2
- Setting: A Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-B01D1 for Injection in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies
- Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
- Enrolled: 38

## Sources

- ClinicalTrials.gov NCT05803018: https://clinicaltrials.gov/study/NCT05803018

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [SystImmune / Sichuan Biokin](https://onco.cc/companies/systimmune/)

---
JSON: https://onco.cc/api/v1/entities/nct05803018.json